Sickle cell drug candidate tested in first human trial – but study halted early
NCT ID NCT05660265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a first-in-human study testing a single dose of an experimental drug called GSK4172239D in 11 people with sickle cell disease. The main goals were to check safety and how the drug moves through the body. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK4172239D (a prodrug that turns into GSK4106401 in the body)
What this could lead to
If successful, this could point toward a new oral treatment option for sickle cell disease.
What could go wrong
This was a very early (Phase 1) trial with only 11 participants, and it was terminated, so results may not be available or applicable. The drug is still experimental and may not prove safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33155, United States
-
GSK Investigational Site
Tamarac, Florida, 33321, United States
-
GSK Investigational Site
Atlanta, Georgia, 30315, United States
-
GSK Investigational Site
Columbus, Georgia, 31904, United States
-
GSK Investigational Site
Riverdale, Georgia, 30274, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States